Literature DB >> 30806840

Long-term outcomes and prognostic factors of pulmonary metastasectomy for osteosarcoma and soft tissue sarcoma.

Yoko Yamamoto1, Ryu Kanzaki2, Takashi Kanou1, Naoko Ose1, Soichiro Funaki1, Yasushi Shintani1, Masato Minami1, Hidetatsu Outani3, Satoshi Takenaka3, Kenichiro Hamada3, Hideki Yoshikawa3, Meinoshin Okumura1.   

Abstract

BACKGROUND: The prognostic factors of pulmonary metastasectomy in patients with osteosarcoma and soft tissue sarcoma remain controversial. The purpose of our analysis was to explore the prognostic factors and outcomes of patients with osteosarcoma and soft tissue sarcoma who underwent pulmonary metastasectomy at our institution.
METHODS: We reviewed the data of 44 patients who underwent resection of pulmonary metastases from 1996 to 2016 at our institution. The Kaplan-Meier method, log-rank test and multivariate Cox hazard model were used for comparison and survival analyses.
RESULTS: There was no perioperative mortality. The median post-metastasectomy overall survival was 24.8 months, and the 5-year overall survival rate of all patients was 43.5%. The 5-year survival rate of the patients who underwent repeat thoracotomies was 60.0%. Incomplete resection, a largest tumor size > 2 cm and a disease-free interval < 12 months were associated with poor survival in multivariate analyses. Among eight patients, who underwent repeat pulmonary resection, two remain alive with no evidence of disease. These patients had the longest DFI and DFI-2 (time from first pulmonary metastasectomy to the diagnosis of recurrent pulmonary metastasis), respectively.
CONCLUSION: The survival of patients with a relatively long disease-free interval, small tumor size and complete resection was favorable following the treatment of osteosarcoma and soft tissue sarcoma with pulmonary metastasectomy. Repeat pulmonary metastasectomies also provide favorable prognosis in select patients.

Entities:  

Keywords:  Osteosarcoma; Pulmonary metastasectomy; Soft tissue sarcoma

Mesh:

Year:  2019        PMID: 30806840     DOI: 10.1007/s10147-019-01422-0

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  12 in total

1.  Follow-Up in Bone Sarcoma Care: A Cross-Sectional European Study.

Authors:  Louren M Goedhart; Andreas Leithner; Joris J W Ploegmakers; Paul C Jutte
Journal:  Sarcoma       Date:  2020-06-30

2.  Trabectedin and Radiation Therapy for Cardiac Metastasis From Leiomyosarcoma: A Case Report and Review of the Literature.

Authors:  Ilaria Tortorelli; Federico Navarria; Antonio Di Maggio; Alberto Banzato; Chiara Lestuzzi; Luca Nicosia; Benedetta Chiusole; Antonella Galiano; Marta Sbaraglia; Vittorina Zagonel; Antonella Brunello
Journal:  Front Oncol       Date:  2022-04-28       Impact factor: 5.738

3.  Pulmonary metastasectomy in soft tissue sarcomas: a systematic review.

Authors:  Davor Stamenovic; Peter Hohenberger; Eric Roessner
Journal:  J Thorac Dis       Date:  2021-04       Impact factor: 2.895

4.  Isovitexin Suppresses Cancer Stemness Property And Induces Apoptosis Of Osteosarcoma Cells By Disruption Of The DNMT1/miR-34a/Bcl-2 Axis.

Authors:  Xiao Liang; Chang Xu; Xiaocheng Cao; Wanchun Wang
Journal:  Cancer Manag Res       Date:  2019-10-15       Impact factor: 3.989

5.  Score for the Risk and Overall Survival of Lung Metastasis in Patients First Diagnosed With Soft Tissue Sarcoma: A Novel Nomogram-Based Risk Assessment System.

Authors:  Zhiyi Fan; Changxing Chi; Yuexin Tong; Zhangheng Huang; Youxin Song; Shengjie You
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

6.  Clinical Outcome in Soft Tissue Sarcoma Patients with Lung Metastasis Who Received Metastasectomy and/or Radiofrequency Ablation: Tokai Musculoskeletal Oncology Consortium Study.

Authors:  Tomoki Nakamura; Kunihiro Asanuma; Motoshi Takao; Takashi Yamanaka; Hiroshi Koike; Toyofumi F Chen-Yoshikawa; Satoshi Tsukushi; Hiroaki Kuroda; Eiji Kozawa; Masaaki Sano; Hisaki Aiba; Ryoichi Nakanishi; Akihito Nagano; Kenji Yamada; Yoji Shido; Katsuhisa Kawanami; Yuya Izubuchi; Akihiro Sudo; Yoshihiro Nishida
Journal:  Cancer Manag Res       Date:  2021-11-10       Impact factor: 3.989

7.  Survival and prognostic factors in patients undergoing pulmonary metastasectomy for lung metastases from retroperitoneal sarcoma.

Authors:  Fumiaki Takatsu; Hiromasa Yamamoto; Yasuaki Tomioka; Shin Tanaka; Kazuhiko Shien; Ken Suzawa; Kentaroh Miyoshi; Shinji Otani; Mikio Okazaki; Seiichiro Sugimoto; Masaomi Yamane; Katsuhito Takahashi; Shinichi Toyooka
Journal:  World J Surg Oncol       Date:  2022-04-08       Impact factor: 2.754

8.  Prognostic Factors for Leiomyosarcoma with Isolated Metastases to the Lungs: Impact of Metastasectomy.

Authors:  Clemens Aigner; Stéphane Collaud; Theresa Stork; Balazs Hegedüs; Wiebke Guder; Rainer Hamacher; Jendrik Hardes; Moritz Kaths; Till Plönes; Christoph Pöttgen; Hans-Ulrich Schildhaus; Arne Streitbürger; Juergen Treckmann; Sebastian Bauer
Journal:  Ann Surg Oncol       Date:  2022-05-12       Impact factor: 4.339

9.  Usefulness of SS18-SSX antibody as a diagnostic marker for pulmonary metastatic synovial sarcoma.

Authors:  Kentaro Miura; Kimihiro Shimizu; Takashi Eguchi; Sachie Koike; Shunichiro Matsuoka; Tetsu Takeda; Kazutoshi Hamanaka; Takeshi Uehara
Journal:  Diagn Pathol       Date:  2021-06-14       Impact factor: 2.644

10.  Long non‑coding RNA H19 regulates LASP1 expression in osteosarcoma by competitively binding to miR‑29a‑3p.

Authors:  Hao Jin; Huan Wang; Xin Jin; Wenbo Wang
Journal:  Oncol Rep       Date:  2021-07-30       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.